Trendlines Group (SGX:42T) said its board approved a capital injection into portfolio companies Ceretrieve and Vensica Medical by controlling shareholder Librae Holdings.
Shares of the agrifood and med-tech company were down over 1% in Tuesday's afternoon trade.
Librae will invest around $850,000 in the units. Additionally, Trendlines will infuse a total of $550,000 to the portfolio firms, according to a Monday filing with the Singapore Exchange.
The funding is aimed at supporting the ongoing operations of the portfolio companies and helping them achieve successful exits, the filing said.
Ceretrieve develops neurointerventional devices, while Vensica Medical specializes in bladder-targeted therapies.